(HEPA) – Accesswire
-
Theralase(R) Announces Appointment of New Independent Director
-
ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update
-
ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials
-
Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
-
Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
-
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
-
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
-
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
-
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
-
Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
-
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
-
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
-
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH
-
Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease
-
Hepion Announces Closing of Public Offering of Common Stock
-
Hepion Pharmaceuticals Prices Public Offering
-
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
-
Hepion Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
-
Hepion Pharmaceuticals to Present at The Liver Meeting Digital Experience(TM) 2020
-
Hepion Pharmaceuticals Completes First Cohort Enrollment in Phase 2a 'AMBITION' Clinical Trial
-
Hepion Pharmaceuticals to Present on Therapeutic Approaches to COVID-19 and NASH at Two Virtual Conferences on October 28 and 29, 2020
-
Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team
-
Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
-
Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases
-
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
-
Hepion Pharmaceuticals to Present CRV431 Preclinical Data at the 2020 Digital International Liver Congress(TM)
-
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431's Antiviral Properties
-
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 'AMBITION' Clinical Trial
-
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
-
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
-
Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis
-
Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors
-
Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
-
Hepion Pharmaceuticals' CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis
-
Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study
-
Anti-Fibrotic Activity of Hepion Pharmaceuticals’ CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases
-
Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
-
Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study
-
Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference
-
Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference
-
Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs
-
Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
-
Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019
-
Hepion Pharmaceuticals Announces Canadian Research Team’s Academic Appointments
-
Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
-
Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
-
Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019
-
Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH
-
Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit
-
Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases
Back to HEPA Stock Lookup
